Trial Profile
A Phase II Study of Nivolumab in Combination With DA-REPOCH Followed by Short Course Nivolumab Consolidation in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Aug 2022
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Nivolumab (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Vincristine (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 18 Aug 2022 Planned End Date changed from 31 Dec 2022 to 31 Jul 2024.
- 18 Aug 2022 Planned primary completion date changed from 31 Dec 2022 to 31 Jul 2024.
- 18 Aug 2022 Status changed from recruiting to active, no longer recruiting.